Heat Biologics: Up on U.S. patent for combination therapy platform

Scorpius Holdings

02/09/2020 13:35

** Shares of biopharmaceutical co  HTBX.O  rise 5.65% to
$1.31 premarket
    ** Co says it has been issued U.S. patent covering
technology that helps activate immune system through key protein
called gp96 (https://bit.ly/32M4uko)
    ** Patent covers combination therapy consisting of co's gp96
platform and an immune booster 
    ** Co says this combination therapy holds "enormous promise"
to treat cancer and infectious diseases, potentially including
COVID-19
    ** Up to last close, HTBX stock up ~161% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))